coiaward2010

CancerWorld article on "Generic cancer drugs that we can trust", covering also the situation in CML with Imatinib going off-patent

2015-03-31 13 29 08-Home - Cancer World - Shaping the future of cancer careGenerics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. It's good news for greater access, but patients want reassurance that switching to generics won't put them at risk. A new CancerWorld article sheds more light on this issue which is increasingly relevant in CML in so many countries, given Imatinib will be off-patent everywhere latest by 2016. The CML Advocates Network​ has pioneered transparency on Imatinib generics (see  http://www.cmladvocates.net/generics) and this is covered in this CancerWorld article, quoting CML Advocates Network members in Lithuania and Serbia... See the full article here


 
   
 

Please donate!

Please donate!

LogIn

Tweet Feed

cmlnet
Call for Abstracts: CML Advocacy Best Practice presentations at CML Horizons 2017.Submit your abstract here… twitter.com/i/web/status/8…

Wednesday, 22 March 2017

VJHemOnc
VIDEO: @jangeissler on new European programs and initiatives relevant to #hematology: ow.ly/HciI309ZN0T @cmlnet #bloodcancer

Retweeted Friday, 17 March 2017

patientpowereu
Factors influencing adherence in CML and ways to improvement ow.ly/FjgD309ZP9H > @cmlnet #CML

Retweeted Friday, 17 March 2017